Home » Bayer Completes Transaction Involving Plasma Business
Bayer Completes Transaction Involving Plasma Business
April 1, 2005
Bayer confirmed it has completed its previously announced transaction to contribute the assets of its worldwide plasma products business to Talecris Biotherapeutics, a newly formed corporation controlled by affiliates of Cerberus Capital Management, New York, and Ampersand Ventures, Wellesley, Mass. The overall transaction volume amounts to approximately $590 million, including cash, a 10 percent equity interest in Talecris Biotherapeutics Holdings, retention of selected working capital items and contingent payments of up to $60 million.
Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050401005262&newsLang=en%20)
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct